Development of a new vascular prosthetic: lessons learned.
In 1972, polytetrafluoroethylene (PTFE) (GoreTex) wire insulation was first implanted into arteries and veins of dogs at the University of Colorado Health Sciences Center in Denver. Subsequent modifications including fibrillar arrangement, wall thickness, and pore size led to the development of a vascular prosthesis with tissue ingrowth, viable neointima, and encouraging patency rates. Tissue culture, surface charge, and platelet studies have all demonstrated the optimal biologic qualities of PTFE grafts. Replacement of one human portal vein by a PTFE graft for invasive carcinoma of the pancreas was strikingly successful. Only unexplained intimal hyperplasia at the arterial anastomotic margins discouraged us from extensive early clinical trials.
D000818:Animals; D001807:Blood Vessel Prosthesis; D004285:Dogs; D005069:Evaluation Studies as Topic; D005260:Female; D005268:Femoral Vein / Q000000981:diagnostic imaging / Q000601:surgery; D006801:Humans; D010190:Pancreatic Neoplasms / Q000601:surgery; D010972:Platelet Activating Factor / Q000502:physiology; D011138:Polytetrafluoroethylene; D011169:Portal Vein / Q000601:surgery; D011859:Radiography; D012107:Research Design; D013552:Swine
D010972:Platelet Activating Factor; D011138:Polytetrafluoroethylene